Cargando…
Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015–2018 Years
BACKGROUND: In Poland drug programmes developed by the Minister of Health and financed by the National Health Fund are special reimbursement frameworks of innovative, expensive, and mostly hospital based medical products used for a small number of patients. RESEARCH DESIGN: The research presented in...
Autores principales: | Mela, Aneta, Poniatowski, Łukasz A., Drop, Bartłomiej, Furtak-Niczyporuk, Marzena, Jaroszyński, Janusz, Wrona, Witold, Staniszewska, Anna, Dąbrowski, Jan, Czajka, Anna, Jagielska, Beata, Wojciechowska, Monika, Niewada, Maciej |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456857/ https://www.ncbi.nlm.nih.gov/pubmed/32922285 http://dx.doi.org/10.3389/fphar.2020.01123 |
Ejemplares similares
-
Economic Costs of Cardiovascular Diseases in Poland Estimates for 2015–2017 Years
por: Mela, Aneta, et al.
Publicado: (2020) -
Brain Functional Reserve in the Context of Neuroplasticity after Stroke
por: Dąbrowski, Jan, et al.
Publicado: (2019) -
Reimbursement decision-making system in Poland systematically compared to other countries
por: Mela, Aneta, et al.
Publicado: (2023) -
Colorectal Cancer—The Worst Enemy Is the One We Do Not Know
por: Furtak-Niczyporuk, Marzena, et al.
Publicado: (2023) -
Are payers treating orphan drugs differently?
por: Cohen, Joshua P., et al.
Publicado: (2014)